CROS NT extends Medidata partnership

By Melissa Fassbender contact

- Last updated on GMT

ICH GCP E6(R2) guidelines outline a risk-based approach to clinical trial monitoring. (Image: iStock/liuzishan)
ICH GCP E6(R2) guidelines outline a risk-based approach to clinical trial monitoring. (Image: iStock/liuzishan)

Related tags: Trial supply management, Contract research organization

The extended partnership provides CROS NT customers access to Medidata’s electronic data capture (EDC) solution as well as its randomization and trial supply management system (RTSM).

Andrew MacGarvey, CEO of CROS NT, told Outsourcing-Pharma.com the company needs a number of systems in its portfolio to serve its customer’s various needs – “and the Medidata products form an important part of our offering​,” he said.

As part of the extended relationship, CROS NT gains access to RaveX, the latest generation of Medidata's EDC system Medidata Rave, and Medidata Balance, a randomization and trial supply management (RTSM) system.

RaveX is an ideal technology to support sponsors implementing a risk-based approach to clinical trials by improving the quality of data coming from sites,”​ MacGarvey said, noting the ICH GCP E6(R2) guidelines​ that come into effect this June.

By adding RaveX to our portfolio of technologies, we are further equipped to help sponsors implement their risk-based clinical and data strategy​,” he added.

Medidata has also trained and accredited the contract research organization’s (CRO) data management team.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars